MKMalgorzata Anna Kolodziej

Malgorzata Anna Kolodziej

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malgorzata Anna Kolodziej has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    L5 Radiculopathy May Induce Changes in Sensory Perception in the Neighboring, Unaffected S1 Dermatome: A Case Control Study

    by Julia Emde, Theda Hansen, Malgorzata Kolodziej, Anne Schänzer, Frank Birklein, Christian Geber, Heidrun H. Krämer

    Neuropathic pain from affection of single nerve roots regularly expands to the neighboring dermatomes. In this study, we aimed to investigate the psychophysical consequences of this pain spread. We performed quantitative sensory testing (QST) in 10 patients with disc herniation—related L5 radiculopathy (four women; age 56.9 ± 2.9 years) and 12 healthy controls (six women; age 55.9 ± 2.7 years) bilaterally in the L5 and S1 dermatomes. Average time between onset of pain and study inclusion was 32 days (+/−6.6). Pain intensity was rated as visual analog scale (VAS) (0–10) 6.5+/−0.6. Affection of the L5 nerve root was verified via clinical investigation, MRI and paravertebral needle electromyography (EMG). The cold ( F = 8.158; p = 0.011) and warm detection ( F = 13.636; p = 0.02) thresholds were higher within the affected L5 dermatome in nucleus pulposus prolapse (NPP) patients compared with controls, and for warm detection also compared with the contralateral side ( p = 0.021). Hyperalgesia to blunt pressure was detected on the affected side in NPP patients compared with controls ( F = 5.664; p = 0.029) and to the contralateral leg ( p = 0.011). Comparing L5 and S1 dermatomes on the affected side, only functional hypoesthesia measure via mechanical detection threshold was increased within the impaired L5 dermatome ( p = 0.043). In the neighboring S1 dermatomes, the warm detection thresholds were significantly increased on the affected side compared with the controls ( F = 14.471; p = 0.001) and to the contralateral unaffected limb ( p = 0.039). In conclusion, unilateral symptomatic L5 damage affects sensory perception in unaffected neighboring dermatomes on the affected limb.

  • Neurosurgical shunt treatment of pediatric hydrocephalus: epidemiology and influencing factors on revision surgeries: a single-center retrospective analysis of 131 patients

    by Jasmin Nagl, Frank P. Schwarm, Michael Bender, Aylin Gencer, Harald Ehrhardt, Andreas Hahn, Bernd A. Neubauer, Malgorzata A. Kolodziej

    Article: Neurosurgical shunt treatment of pediatric hydrocephalus: epidemiology and influencing factors on revision surgeries: a single-center retrospective analysis of 131 patients - Minerva Pediatrics 2022 Oct 25 - Minerva Medica - Journals


  • ZEB1 induces N‑cadherin expression in human glioblastoma and may alter patient survival

    by Hanna Gött, Jasmin Nagl, Frederike Hagedorn, Samuel Thomas, Frank P. Schwarm, Eberhard Uhl, Malgorzata A. Kolodziej

    The present study investigated the expression of epithelial‑mesenchymal transition (EMT)‑related factors zinc finger E‑box‑binding homeobox 1 (ZEB1), cadherin‑1 (CDH1), cadherin‑2 (CDH2) and the cell cycle modulating kinase cyclin‑dependent kinase 1 (CDK1) in human glioblastoma (GBM) compared to normal brain tissue, as well as whether the levels of expression were associated with the overall and progression‑free survival of the GBM patients. In 44 GBM and five normal brain tissue specimens, the expression levels of ZEB1, CDH1, CDH2 and CDK1 were evaluated by real‑time PCR and immunostaining, and the results were correlated with clinical data. The expression levels of all investigated genes as detected by immunostaining were significantly higher in the GBM when compared to the normal brain tissues. There was no influence on survival. A linear correlation between ZEB1 and CDH2 and CDK1 expression was observed in GBM. Moreover, ZEB1 was involved in EMT (e.g., signaling in human GBM) and high ZEB1 levels were linked to an aberrant cell cycle processing, marked by CDK1 overexpression.


  • Antiproliferative effect of GTS‑21 in glioblastoma cells

    by Malgorzata A. Kolodziej, Hanna Gött, Benjamin Kopischke, Michael K.F. Bender, Markus A. Weigand, Pietro Di Fazio, Frank P. Schwarm, Florian Uhle

    Glioblastoma multiforme (GBM) is the most common malignant brain tumour in adults. The poor prognosis and short median overall survival of patients with GBM is associated with resistance to therapy after surgical and adjuvant treatment. The expression of various acetylcholine receptors (AChR) in GBM has been widely reported. The present study aimed to investigate the expression of cholinergic system‑related genes in primary GBM and to explore the antiproliferative effect of 3‑(2,4‑dimethoxybenzylidene) anabaseine (GTS‑21) in GBM cell lines. Therefore, the expression of 28 genes associated with the cholinergic system was detected using a customized RT2 Profiler PCR Array in 44 GBM and 5 healthy control brain tissue samples. In addition, the activity of GTS‑21, an alpha 7 subunit nicotinic AChR (α7 nAChR) agonist, and that of α‑bungarotoxin (α‑BTX), an α7 nAChR antagonist, was determined in primary and established GBM cells. Therefore, the A172, U87 and G28 cell lines and primary GBM cells were treated with GTS‑21, ACh or nicotine. Cell viability was evaluated using MTT assay at 24, 48 and 72 h following cell treatment with the corresponding compounds. The results revealed that the expression of cholinergic system‑related components was notably downregulated, except that of cholinergic receptor nicotinic alpha 7 subunit (CHRNA7), in primary GBM and U87 cells. However, the dominant‑negative duplicate form of CHRNA7 was also downregulated. Furthermore, A172 and G28 cells exhibited a heterogeneous gene expression pattern. Additionally, GTS‑21 inhibited the proliferation of GBM cells in a dose‑ and time‑dependent manner. Interestingly, treatment with α‑BTX restored the proliferation of U87 cells, but not that of A172 and G28 cells. Collectively, the findings of the present study suggested that GTS‑21 may inhibit the proliferation of GBM cells and may therefore serve as a novel therapeutic approach to the treatment of GBM, which warrants further investigation.


  • Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells

    by M. A. Kolodziej, B. Al Barim, J. Nagl, M. A. Weigand, E. Uhl, F. Uhle, P. Di Fazio, F. P. Schwarm, M. Stein

    Sphingosine‑1‑phosphate (S1P) plays a key role in cell survival, growth, migration, and in angiogenesis. In glioma, it triggers the activity of the S1P‑receptor 1 and of the sphingosine kinase 1; thus influencing the survival rate of patients. The aim of the present study was to investigate the anti‑proliferative effect of the S1P analogue FTY720 (fingolimod) in glioblastoma (GBM) cells. A172, G28, and U87 cells were incubated with micromolar concentrations of FTY720 or temozolomide (TMZ) for 24 to 72 h. Proliferation and half maximal inhibitory concentration (IC50) were determined by using the xCELLigence system. FACS analysis was performed to check the cell cycle distribution of the cells after a 72‑h incubation with FTY720. This was then compared to TMZ‑incubated and to untreated cells. Gene expression was detected by RT‑qPCR in A172, G28, U87 and three primary GBM‑derived cell lines. FTY720 was able to reduce the number of viable cells. The IC50 value was 4.6 µM in A172 cells, 17.3 µM in G28 cells, and 25.2 µM in U87 cells. FTY720 caused a significant arrest of the cell cycle in all cells and stabilized or over‑expressed the level of AKT1, MAPK1, PKCE, RAC1, and ROCK1 transcripts. The TP53 transcript level remained stable or was downregulated after treatment with FTY720. FTY720 may be a promising target drug for the treatment of GBM, as it has a strong anti‑proliferative effect on GBM cells.


  • The Predictive Value of Transcutaneous Electrical Nerve Stimulation for Patient Selection in Peripheral Nerve Field Stimulation for Chronic Low Back Pain: A Prospective Study

    by Frank Patrick Schwarm, Marc Ott, Jasmin Nagl, Michael Bender, Marco Stein, Eberhard Uhl, Hagen Maxeiner, Malgorzata A. Kolodziej


  • Interdisciplinary Laparoscopic Implantation of Neuromodulation Leads to the Sacral Plexus for Therapy of Chronic Pelvic Pain and Neurogenic Bladder Dysfunctions

    by Malgorzata Kolodziej, Eberhard Uhl, Frank Schwarm, Jasmin Nagl, Rainer Schürg, Ivo Meinhold-Heerlein, Hans-Rudolf Tinneberg


  • Programmable valve breakage in shunt systems of children with posthemorrhagic hydrocephalus after minor head trauma—a case series

    by Frank P. Schwarm, Jasmin Nagl, Michael Bender, Marco Stein, Kerstin Giese, Andreas Hahn, Eberhard Uhl, Malgorzata A. Kolodziej

    Purpose We report five rare cases of programmable valve breakage (Codman Hakim-Medos valve) in shunt systems of children with posthemorrhagic hydrocephalus. Only four similar studies have been published in the current literature. Methods Between 2013 and 2018, five children with posthemorrhagic hydrocephalus were admitted to the pediatric department. All patients had a history of slight blows to the head in a minor trauma and follow up MRI scans. After initial clinical examination, cranial computed tomography (CT) and X-ray were conducted. Results In all cases, pumping the reservoir resulted in very slow refilling. The cranial CT in one patient showed slit ventricles confirming the suspicion of overdrainage, the other cases a slight enhancement of the hydrocephalus. In lateral X-rays of the skull in comparison to the first X-ray control of the shunt valve, the pressure control chamber could be seen dislocated in the inferior part of the reservoir in all cases. Surgery revealed that the shunt valve was broken. The pressure control chamber had dropped to the bottom of the reservoir. After implantation of a new shunt valve, the symptoms resolved completely in all five children. Overall this complication occurred in 4.3% (5 of 85 implanted Codman Hakim-Medos valve) of all children necessitating ventriculoperitoneal shunt implantation between January 2013 and December 2018. Conclusion The well-accepted Codman Hakim-Medos programmable valve is part of a tube-system, which is designed to offer the possibility of a reliable and precise treatment of hydrocephalus. Various mechanical and non-mechanical complications of shunt systems have been reported. Valve breakage is a very rare condition, often missed, and must be kept in mind when trauma and prior MRI scan are reported.


    • 1 March 2016
      • Vol. 36  (3) , 887-97

    NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors.

    by Malgorzata A Kolodziej, Cornelia Weischer, Marcus H T Reinges, Eberhard Uhl, Marcus A Weigand, Frank P Schwarm, Anne Schänzer, Till Acker, Karl Quint, Florian Uhle, et al.

    The N-myc down-regulated gene (NDRG) family is a group of genes that have predominantly tumor-suppressive effects. The goal of this study was to investigate the expression of NDRG2 and NDRG4 in surgical specimens of human glioblastoma and in normal brain tissue, and to search for correlations with overall (OS) and progression-free survival (PFS). Samples from 44 patients (31 males, 13 females; mean age±SD=57.4±15.7 years) with primary (n=40) or recurrent glioblastoma (n=4) were analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry, with dimensionless semiquantitative immunoreactivity score (IRS), ranging from 0-30] for expression of NDRG2 and NDRG4. Five non-tumorous autopsy brain specimens were used as controls. On the protein level, expression of NDRG2 was significantly down-regulated in glioblastoma (IRS=3.5±3.0 vs. 8.8±3.3; p=0.001), while expression of NDRG4 was significantly up-regulated (IRS=5.4±3.7 vs. 0.75±0.4 vs, p<0.001). There was no statistically significant difference in PFS between a group of 15 patients with glioblastoma with MGMT methylation and enhanced expression of NDRG4 mRNA who were treated with adjuvant radiochemotherapy (temozolomide and 60 Gy) and a group of patients with low expression of NDRG4 mRNA [10 (range=5.5-14.2) months vs. 21 (range=10.7-31.3) months] (p=0.13). Expression of both NDRG2 and NDRG4 genes is significantly altered in glioblastomas. PFS among the patients with glioblastoma with MGMT methylation treated with radiochemotherapy differed significantly in high-expression groups compared to patients without MGMT methlation and without radiochemotherapy (p<0.05).